登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
HAIC, Lenvatinib, and Cadonilimab as Conversion Therapy for Initially Unresectable Hepatocellular Carcinoma
ClinicalTrials.gov 上登记的一项肝细胞癌开放试验,由华中科技大学同济医学院附属同济医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT06187961,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 8
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(8 项)收起清单
18 岁 至 未注明;性别:不限
登记记录的入选字段
Hepatocellular carcinoma proven on biopsy or confirmed by radiological hallmarks according to the American Association for the Study of Liver Diseases (AASLD) or the European Association for the Study of the Liver (EASL) guidelines.
入选标准第 1 条
Child-Pugh score ≤7.
入选标准第 18 条
Symptomatic congestive heart failure (NYHA class II-IV) or left ventricular ejection fraction <50%.
排除标准第 12 条
According to RECIST version 1.1, at least 1 measurable lesion, or a measurable lesion that has clearly progressed after local treatment.
入选标准第 9 条
Prior treatment with anti-PD-1, anti-PD-L1/L2, anti-CTLA-4, or other immunotherapy, or prior targeted therapy against VEGF/VEGFR, RAF, MEK, PDGFR, FGFR, or related pathways.
排除标准第 28 条
Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
入选标准第 3 条
Absolute neutrophil count ≥1.5×10\^9/L; platelet count ≥75×10\^9/L; hemoglobin ≥9.0 g/dL.
入选标准第 20 条
Total bilirubin ≤2× upper limit of normal (ULN); ALT and AST ≤5× ULN; serum albumin ≥28 g/L; alkaline phosphatase ≤5× ULN.
入选标准第 21 条
Serum creatinine ≤1.5× ULN or creatinine clearance ≥50 mL/min; urine protein <2+; if urine protein ≥2+, 24-hour urinary protein must be <1 g.
入选标准第 22 条
Continuous use of aspirin >325 mg/day or other known platelet inhibitors for 10 days within 2 weeks before first dose.
排除标准第 9 条
Active pulmonary tuberculosis, current anti-tuberculosis treatment, or anti-tuberculosis treatment within 1 year before first dose.
排除标准第 18 条
HIV infection or known syphilis requiring treatment.
排除标准第 19 条
Other malignancy diagnosed within 5 years before first dose, except radically treated basal cell carcinoma, squamous cell carcinoma of the skin, or carcinoma in situ.
排除标准第 27 条
Female participants of childbearing potential, or male participants whose partners are of childbearing potential, must agree to use effective contraception during study treatment and for 6 months after the last dose.
入选标准第 25 条
Pregnancy or breastfeeding.
排除标准第 32 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:影像与可测量病灶。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06187961,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Hepatocellular carcinoma proven on biopsy or confirmed by radiological hallmarks according to the American Association for the Study of Liver Diseases (AASLD) or the European Association for the Study of the Liver (EASL) guidelines. Age ≥18 years. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1. Not suitable for curative-intent treatment (including radical hepatic resection, liver transplantation, or curative ablation) after evaluation by the hepatobiliary tumor MDT expert group. Specifically, any of the following conditions are met: R0 resection is not feasible. In participants without cirrhosis, the volume of normal liver parenchyma is less than 30% of the total liver volume; or in participants with cirrhosis, the volume of normal liver parenchyma is less than 40% of the total liver volume; or ICG-R15 >15%. BCLC stage B or C. No prior systemic anti-tumor treatment for hepatocellular carcinoma before the first dose. According to RECIST version 1.1, at least 1 measurable lesion, or a measurable lesion that has clearly progressed after local treatment. Participants with portal vein tumor thrombus (PVTT): Chen's group A and B, or Cheng's type I-III, can be enrolled. Cheng's type IV, defined as superior mesenteric vein tumor thrombus, cannot be enrolled. Participants with hepatic vein tumor thrombus: VV1 and VV2 can be enrolled. VV3, or Sakamoto type I (inferior vena cava tumor thrombus), can also be enrolled. Sakamoto type II (inferior vena cava tumor thrombus extending above the diaphragm) or Sakamoto type III (inferior vena cava tumor thrombus reaching the right atrium) cannot be enrolled. Participants with oligometastases outside the liver can be enrolled. Oligometastases are defined as up to three metastatic lesions in a maximum of two organs, with the largest diameter ≤3 cm. Child-Pugh score ≤7. Adequate organ and bone marrow function within 7 days before enrollment: Absolute neutrophil count ≥1.5×10\^9/L; platelet count ≥75×10\^9/L; hemoglobin ≥9.0 g/dL. Total bilirubin ≤2× upper limit of normal (ULN); ALT and AST ≤5× ULN; serum albumin ≥28 g/L; alkaline phosphatase ≤5× ULN. Serum creatinine ≤1.5× ULN or creatinine clearance ≥50 mL/min; urine protein <2+; if urine protein ≥2+, 24-hour urinary protein must be <1 g. INR ≤2.3 or prothrombin time prolongation ≤6 seconds. Estimated life expectancy ≥12 weeks. Female participants of childbearing potential, or male participants whose partners are of childbearing potential, must agree to use effective contraception during study treatment and for 6 months after the last dose. Signed written informed consent and ability to comply with study visits and procedures.排除标准:Exclusion Criteria:
Histologically or cytologically confirmed fibrolamellar hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma, cholangiocarcinoma, or mixed histology. History of hepatic encephalopathy or liver transplantation. Clinically symptomatic pleural effusion, ascites, or pericardial effusion requiring drainage. Participants with only minimal radiologic effusion without symptoms may be enrolled. Acute or chronic active hepatitis B or C infection, with HBV DNA >2000 IU/mL or 10\^4 copies/mL, HCV RNA >10\^3 copies/mL, or co-positivity for HBsAg and anti-HCV antibody. Participants controlled to within these limits after antiviral therapy may be enrolled. Central nervous system metastases. History of esophageal or gastric variceal bleeding due to portal hypertension within 6 months before first dose, or high bleeding risk judged by the investigator. Any life-threatening bleeding event within 3 months before first dose. History of arterial or venous thromboembolic events within 6 months before first dose, including myocardial infarction, unstable angina, cerebrovascular accident, transient ischemic attack, pulmonary embolism, deep vein thrombosis, or other serious thromboembolic events, except stabilized catheter-related thrombosis or superficial thrombosis. Continuous use of aspirin >325 mg/day or other known platelet inhibitors for 10 days within 2 weeks before first dose. Uncontrolled hypertension despite optimal treatment, defined as systolic blood pressure ≥150 mmHg or diastolic blood pressure ≥100 mmHg, or history of hypertensive crisis or hypertensive encephalopathy. Toxicities from previous treatment not recovered to grade 0 or 1 per NCI-CTCAE version 5.0, except alopecia or clinically insignificant asymptomatic laboratory abnormalities. Symptomatic congestive heart failure (NYHA class II-IV) or left ventricular ejection fraction <50%. Symptomatic or poorly controlled arrhythmia, history of congenital long QT syndrome, or screening QTc >500 ms by Fridericia formula. Severe bleeding tendency, coagulation disorder, or current thrombolytic therapy. Gastrointestinal perforation or fistula, intestinal obstruction, extensive bowel resection with chronic diarrhea, Crohn's disease, ulcerative colitis, or chronic diarrhea within 6 months before first dose. Radiotherapy within 3 weeks before first dose, unless all radiation-related toxicities have resolved and there is no need for corticosteroids. Pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, drug-related pneumonia, severe pulmonary dysfunction, or other severe lung disease. Active pulmonary tuberculosis, current anti-tuberculosis treatment, or anti-tuberculosis treatment within 1 year before first dose. HIV infection or known syphilis requiring treatment. Active or clinically uncontrolled severe infection within 4 weeks before first dose. Active autoimmune disease requiring systemic treatment within 2 years before first dose, except replacement therapy. Use of immunosuppressive drugs within 4 weeks before first dose, except local or physiologic-dose corticosteroids and temporary corticosteroids for allergy or airway symptoms. Live attenuated vaccine within 4 weeks before first dose or planned during the study period. Major surgery or unhealed wound, ulcer, or fracture within 4 weeks before first dose. Local treatment for hepatocellular carcinoma within 4 weeks before first dose. Traditional Chinese medicine with anti-tumor indications, or immunomodulatory drugs such as thymosin, interferon, or interleukin, within 2 weeks before first dose. Other acute or chronic diseases, psychiatric disorders, or laboratory abnormalities that, in the investigator's judgment, increase risk or interfere with study interpretation. Other malignancy diagnosed within 5 years before first dose, except radically treated basal cell carcinoma, squamous cell carcinoma of the skin, or carcinoma in situ. Prior treatment with anti-PD-1, anti-PD-L1/L2, anti-CTLA-4, or other immunotherapy, or prior targeted therapy against VEGF/VEGFR, RAF, MEK, PDGFR, FGFR, or related pathways. Known allergy to oxaliplatin, fluorouracil, leucovorin, lenvatinib, cadonilimab, or severe prior allergic reaction to other monoclonal antibodies. Aortic dissection aneurysm, celiac trunk dissection aneurysm, or superior mesenteric artery dissection aneurysm. Participation in another clinical trial within 4 weeks before first dose. Pregnancy or breastfeeding. Systemic multiple metastases, portal vein tumor thrombus involving the superior mesenteric vein, or inferior vena cava tumor thrombus extending above the diaphragm or reaching the right atrium. Any other condition that, in the investigator's judgment, makes the participant unsuitable for the study.
引自 ClinicalTrials.gov, NCT06187961, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06187961,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。